$69.5B
2025 sales, these 4 drugs
Lilly $36.5B + Novo $33B — what was at stake
~9×
Price jump patients faced
~$200/mo compounded → ~$1,000-1,800/mo brand
$91-310
What it costs elsewhere
France, UK, Canada, Australia — same drug, per month
Jan 2026
Patent holders sued the competition
Compounder's federal antitrust suit against Lilly & Novo
This isn't complicated once you see the shape of it. A shortage made cheap copies legal. Millions got healthy on them. The shortage ended, the cheap copies became illegal by law, and the two companies who make the patented originals — who profit directly and enormously every time a patient can't get the $200 version — pushed hard, in public filings and in court, to make sure it stays that way. Both a real safety case AND a massive financial motive are true at the same time. Don't let either one erase the other.
#1 — THE DRUGS WORK
Undisputed
Semaglutide and tirzepatide produce real weight loss and real diabetes control. Nobody disputes the drugs themselves. The fight is entirely about who's allowed to make them cheaply.
#2 — THE CHEAP VERSION
Made illegal by law
Licensed pharmacies made the same active drug for ~$200/month during the shortage. The instant the shortage was declared over, that became illegal to sell — not because it stopped working.
#3 — WHO ASKED FOR THE BAN
Follow it
Novo Nordisk petitioned the FDA directly to block compounding. Lilly and Novo both sued compounding pharmacies. A compounder is now suing them back for antitrust violations. Weigh who had the motive.
The whole story is in this one picture. Compounded, it was ~$200/month. Once that was shut off, the "cheapest legal" option in the US jumped to $350-500 (manufacturer cash vials) and the sticker price is $1,000-1,800. Meanwhile the identical drug, same molecule, costs a fraction of the US brand price in the UK, France, Canada, and Australia — because those governments negotiate price or allow generics the US delayed.
Compounded (US, gone)
Now illegal to sell
Rest of the World
UK ~$100-239 · France ~$91 · Canada ~$167-310 · Australia ~$98
Lilly/Novo Cash Vials
The patent holders' own "discount," lower doses only
US Brand List Price
Wegovy ~$1,349 · Ozempic ~$1,000-1,400
Follow the money. The same molecule that costs ~$1,000-1,800/month at US list price costs roughly $91/month in France, $100-239/month in the UK, and $98/month in Australia — because those countries negotiate a price or cap it through national health systems. The US has neither. Compounding was the one crack in that wall for American patients, and it's the crack that just got sealed. (These are different price types — manufacturer list, public-payer rate, or patient cost — and aren't perfectly apples-to-apples, but the multi-hundred-dollar gap to the US list price is consistent across every country checked.)
None of this was a scam or a loophole — it was the law working exactly as written, right up until it stopped working for patients. Watch how fast it moved once the two patent holders had a financial reason to want it closed.
| Date | What happened | Who benefited |
|---|
| 2022 | FDA puts semaglutide & tirzepatide on the Drug Shortage List — demand outstripped Lilly/Novo's supply | Patients — compounding becomes legal |
| 2022-2024 | Compounders & telehealth (Hims, Ro, others) sell the same active drug for ~$200/month; millions gain access, many insured | Patients & compounders |
| Oct 2024 | Novo Nordisk files an FDA citizen petition asking to add semaglutide to the "Demonstrable Difficulties for Compounding" list — a request that, if granted, blocks compounding even during future shortages | Novo Nordisk — targets its own cheap competition |
| Dec 19, 2024 | FDA removes tirzepatide from the shortage list on Lilly's supply claim | Clock starts on compounding ban |
| Feb 21, 2025 | FDA declares semaglutide shortage resolved | Clock starts on compounding ban |
| Feb-May 2025 | Compounding deadlines hit for both drugs (503A/503B); the cheap version becomes illegal to sell nationwide | Lilly & Novo — competition removed by law |
| Apr 24, 2025 | Federal court denies compounders' injunction (Outsourcing Facilities Assoc. v. FDA) | Lilly & Novo — last legal challenge fails |
| Jun 2025 | Novo Nordisk terminates its telehealth partnership with Hims & Hers, citing "illegal mass compounding"; sues Hims for patent infringement | Novo Nordisk — cuts off a major compounded-drug seller |
| Sep 2025 | FDA issues 55+ warning letters to online sellers of compounded GLP-1s in a single action — the largest enforcement sweep in GLP-1 history | Lilly & Novo |
| Jan 14, 2026 | Strive Compounding Pharmacy files a federal antitrust lawsuit against Lilly and Novo Nordisk, alleging coordinated exclusive-dealing agreements with telehealth platforms designed to kill compounded competition | Compounders push back — case pending |
| Feb 24, 2026 | Novo Nordisk announces it will cut Wegovy's US list price up to 50% (Ozempic 35%) — starting 2027, not now — citing "growing competition" | Announced only after losing the cheap competition it just helped remove |
| Mar 2026 | Novo Nordisk drops its lawsuit against Hims & Hers and signs a new deal — Hims sells Novo's branded drugs and stops advertising compounded alternatives | Novo Nordisk — converts a competitor into a distributor |
| Apr 2026 | Health Canada approves the first generic semaglutide, widening the US-Canada price gap further | Canadian patients get a cheap legal option the US still doesn't have |
| 2026 (pending) | FDA proposal to permanently bar these drugs from bulk compounding — would block the shortage safety-valve even in a future shortage; public comment period ran through June 29, 2026 | Would lock in the current arrangement for good |
The FDA and the two manufacturers are not neutral referees here — they are the parties who benefit financially from the outcome. Present their case fully, but don't mistake it for the verdict. A federal antitrust lawsuit is now testing the other side's claim in court.
Lilly & Novo Nordisk's Position
"The shortage genuinely ended and the law required it"
Both companies say they invested billions in new manufacturing and the shortage really did resolve. Novo's citizen petition and lawsuits cite FDA adverse-event reports on compounded products — dosing errors, unapproved salt forms, contamination — as reasons compounding should stop even during a future shortage. Their public framing is entirely about patient safety and legal compliance.
The Antitrust Case (Compounders, in federal court)
"Coordinated conduct to kill lawful competition"
Strive Specialties Inc. v. Eli Lilly & Co. et al. (W.D. Texas, filed Jan 14, 2026) alleges Lilly and Novo Nordisk entered exclusive agreements with telehealth platforms that barred those platforms from working with compounding pharmacies — coordinated conduct, not just individual company decisions, aimed at discouraging providers and patients from using compounded GLP-1s that undercut brand prices by 80-90%. This is a live federal case, not settled fact either way.
What's not in dispute: the shortage was real; compounding was 100% legal while it lasted; millions got affordable access; that access ended by law once the shortage was declared over; Novo separately petitioned to make compounding illegal even in a future shortage; and Novo announced a 50% list-price cut — not effective until 2027 — only after a compounder sued them for antitrust violations and a generic launched in Canada. The disagreement is about motive, and a federal court is now the venue deciding it.
This is where the doctrine matters most: don't let a profit-driven ban borrow credibility from inflated safety fears, but don't pretend the safety concern is fake either. Here's what the actual pharmacovigilance data shows, plainly.
The real signal in the data
Elevated risk
A 2025 FDA Adverse Event Reporting System analysis of 81,078 GLP-1 reports (2018-2024) found compounded products carried higher reporting odds for dosing/preparation errors (nearly 49× for preparation errors), contamination (19×), and hospitalization (2.35×) versus manufactured pens. A separate poison-control case series documented 10-fold dosing errors from vial-and-syringe compounded semaglutide with no pharmacist counseling. This is real and worth taking seriously.
What that data does NOT prove
Correlation ≠ ban
The FAERS study itself is a pharmacovigilance signal, not a controlled trial — self-reported, subject to reporting bias, and it studied a market that included both licensed 503A/503B pharmacies AND unregulated gray-market sellers lumped together. The compounding-industry group (Alliance for Pharmacy Compounding) argues synthetic semaglutide APIs from licensed facilities show comparable or better impurity profiles than Novo's own recombinant API, and that the fix for dosing/labeling errors is better pharmacist counseling and regulation — not a total ban that also removes the $800-1,600/month price gap.
The honest read: licensed compounding under real pharmacist oversight is not the same risk as an unregulated vial off a gray-market website, and the data blending them together is genuinely used both ways — by the industry to justify a total ban, and by compounders to argue for better regulation instead. A total ban solves the safety problem by also removing the only affordable legal option for a captive market of patients who can't pay $1,000+/month. Weigh both.
Illegal now
US Compounded
~$200
/month, banned 2025
Cheapest legal, int'l
UK / France / Australia
$91-239
/month, negotiated price
Manufacturer's own deal
LillyDirect / NovoCare
$350-500
/month, self-pay, lower doses only
US Brand, no coverage
$1,000-1,800
/month list (2026); Novo has announced a cut to ~$675 starting 2027
The Patients Cut Off Representative outcome, not a controlled study
Someone gets on compounded GLP-1 during the shortage, insurance covers the cheaper price, they lose 30+ pounds and their blood sugar and blood pressure normalize. Then the shortage is declared over, their compounder is shut down, insurance won't cover the pricier brand for weight loss, and they can't afford $1,000+/month. The health gains start unwinding through no fault of their own. Multiply by however many of the millions who relied on the compounded price couldn't absorb a 9× increase. →
NBC News — the affordability gap
Nate Hill Co-founder/CEO, Strive Specialties (compounding pharmacy)
Filed the January 2026 federal antitrust suit against Lilly and Novo, alleging coordinated exclusive-dealing conduct built to kill compounded competition. On the record: "Fair competition is an essential part not only of this industry, but the entire economy." He has no patent to protect and no $69.5 billion in brand sales riding on the outcome — the opposite financial position from the two defendants. →
Strive lawsuit announcement
The Outsourcing Facilities Association Trade group, 503B compounding pharmacies
Sued the FDA twice (Oct 2024 over tirzepatide, early 2025 over semaglutide), calling the shortage-resolution determination "reckless and arbitrary" and arguing real supply gaps remained for many patients. A federal court denied their injunction April 24, 2025 — they lost, but the underlying claim (that "resolved" was declared prematurely, to the direct financial benefit of the manufacturers) was never fully litigated on the merits. →
Fierce Pharma — the lawsuits
Lilly & Novo Nordisk Patent holders — $36.5B and $33B in 2025 sales from these drugs
Both point to billions invested in manufacturing capacity and real, documented safety incidents in the compounded market as their reasons. Both are also the parties who gain a combined $69.5 billion a year when the $200 competition disappears, who separately petitioned regulators and sued sellers of that competition, and who announced a price cut — not effective until 2027 — only after losing a major distribution partner to compounding pressure and getting sued for antitrust violations. Both things are true. Judge the timing for yourself. →
Medical Economics — the stakes
The Bottom Line — In Plain English
What happened: A real drug shortage made it legal for pharmacies to compound cheap copies of Ozempic, Wegovy, Mounjaro, and Zepbound. Millions of Americans got healthy on the ~$200/month version. When the shortage officially ended, that became illegal by law — and the price patients faced snapped back up roughly 9×, to $1,000-1,800/month.
Follow the money: Eli Lilly and Novo Nordisk made a combined $69.5 billion in 2025 from these four drugs. They petitioned regulators to make compounding illegal even in future shortages, sued compounding pharmacies and telehealth platforms selling it, and cut off a major distribution partner over it. A compounder is now suing them back in federal court for coordinated antitrust conduct. Only after all of that did Novo announce a price cut — and it doesn't take effect until 2027.
The rest of the world pays far less: The identical drug costs roughly $91/month in France, $100-239 in the UK, $98 in Australia, and Canada just approved its first generic. The US is the outlier, not the norm — and compounding was the one workaround that briefly closed that gap for American patients.
Safety, honestly: Real pharmacovigilance data shows higher error and contamination rates in the compounded market — that's not manufactured fear, it's in the FDA's own adverse-event database. But that data blends licensed, pharmacist-overseen compounding with unregulated gray-market sellers, and a total ban solves the safety problem in the same stroke it removes the only affordable option millions relied on. Better regulation and a total ban are not the same policy, and only one of them also protects $69.5 billion in sales.
- Compounded GLP-1s were 100% legal while the shortage lasted — legally shut down once it "ended," not because the drug changed.
- Lilly + Novo made $69.5B in 2025 from the four brand drugs — the financial stakes in this crackdown are enormous and one-sided.
- Novo Nordisk directly petitioned the FDA to ban compounding, sued sellers of it, and cut a major telehealth partner off from it.
- A federal antitrust lawsuit (Strive v. Lilly & Novo, filed Jan 2026) accuses the two companies of coordinated conduct to kill the cheap competition — pending in court, not settled.
- The same drug costs a fraction of the US price in France, the UK, Canada, and Australia — this is a US pricing/policy problem, not a global one.
- Real safety data on compounded products exists and should be taken seriously — but it doesn't require a total ban, and the party pushing hardest for the ban profits enormously from it.